

Akihiro Yoshida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7078419/publications.pdf>

Version: 2024-02-01

11
papers

484
citations

1040056

9
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

1073
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. <i>Cancer Research</i> , 2016, 76, 2990-3002.	0.9	123
2	A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. <i>Nature Cell Biology</i> , 2018, 20, 104-115.	10.3	86
3	MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4201-4214.	7.0	77
4	Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. <i>Nature Communications</i> , 2019, 10, 1296.	12.8	73
5	PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. <i>PLoS Genetics</i> , 2016, 12, e1006518.	3.5	41
6	SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. <i>Science Advances</i> , 2019, 5, eaax6352.	10.3	31
7	Consequence of the tumor-associated conversion to cyclin D1b. <i>EMBO Molecular Medicine</i> , 2015, 7, 628-647.	6.9	19
8	Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. <i>PLoS ONE</i> , 2017, 12, e0177830.	2.5	17
9	Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3. <i>Oncogene</i> , 2021, 40, 292-306.	5.9	13
10	Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss. <i>Oncogene</i> , 2022, 41, 2187-2195.	5.9	4
11	Effect of bypass kinase pathways on acquired CDK4/6 inhibitor resistance.. <i>Journal of Clinical Oncology</i> , 2018, 36, 379-379.	1.6	0